News
Neurocrine and Xenon agree $1.75bn epilepsy R&D tie-up
Two biotechs, Neurocrine Biosciences and Xenon, have announced a licence and collaboration agreement to develop first-in-class treatments for epilepsy in a deal worth up to $1.75 billion.
